|
|
 |
|
|
|
|
Compressible sugar, 122 |
|
|
|
|
|
|
|
|
Computer-aided drug design (CADD), 204-215 |
|
|
|
|
|
|
|
|
definition, 204 |
|
|
|
|
|
|
|
|
drug discovery, 209-210 |
|
|
|
|
|
|
|
|
future of, 213 |
|
|
|
|
|
|
|
|
requirements, 210-213 |
|
|
|
|
|
|
|
|
techniques, 205-209 |
|
|
|
|
|
|
|
|
Computer assisted product license applications (CAPLAs), 437, 438 |
|
|
|
|
|
|
|
|
Computer Optimized Parametric Analysis of Chemical Toxicity (COMPACT), 223 |
|
|
|
|
|
|
|
|
Concentration |
|
|
|
|
|
|
|
|
dose, 21 |
|
|
|
|
|
|
|
|
measurements, 21 |
|
|
|
|
|
|
|
|
serum, 21 |
|
|
|
|
|
|
|
|
Continuous reassessment method (CRM), 288 |
|
|
|
|
|
|
|
|
Contract Research Organization (CRO), 13, 14, 84, 317-334, 340-351 |
|
|
|
|
|
|
|
|
CRO |
|
|
|
|
|
|
|
|
advantages of, 322 |
|
|
|
|
|
|
|
|
definition, 341 |
|
|
|
|
|
|
|
|
disadvantages of, 322-323 |
|
|
|
|
|
|
|
|
evaluating the need for, 323 |
|
|
|
|
|
|
|
|
evaluation of, 333 |
|
|
|
|
|
|
|
|
factors affecting success with, 345 |
|
|
|
|
|
|
|
|
process of contracting out to, 323-326 |
|
|
|
|
|
|
|
|
project implementation with, 346-351 |
|
|
|
|
|
|
|
|
rationale for using, 343-344 |
|
|
|
|
|
|
|
|
selection, 326-330 |
|
|
|
|
|
|
|
|
Customer intimacy, 41 |
|
|
|
|
|
|
|
|
Delivery systems |
|
|
|
|
|
|
|
|
novel, 9, 170-190 |
|
|
|
|
|
|
|
|
Development portfolio, 106-107 |
|
|
|
|
|
|
|
|
Dextrates, 123 |
|
|
|
|
|
|
|
|
Dextrose, 123 |
|
|
|
|
|
|
|
|
Discovery portfolio, 104-106 |
|
|
|
|
|
|
|
|
Dissolution testing, 128-154 |
|
|
|
|
|
|
|
|
Dosage form design, 128-154 |
|
|
|
|
|
|
|
|
Drug acquisition, 282-284 |
|
|
|
|
|
|
|
|
Drug delivery, 9 |
|
|
|
|
|
|
|
|
buccal, 179-181 |
|
|
|
|
|
|
|
|
nasal, 181 |
|
|
|
|
|
|
|
|
novel, 170-192 |
|
|
|
|
|
|
|
|
oral, 173-176 |
|
|
|
|
|
|
|
|
parenteral, 182-183 |
|
|
|
|
|
|
|
|
pulmonary, 181-182 |
|
|
|
|
|
|
|
|
pulsatile, 190 |
|
|
|
|
|
|
|
|
transdermal, 176-179 |
|
|
|
|
|
|
|
|
Drug development, 2, 3, 13, 14 |
|
|
|
|
|
|
|
|
anticancer, 282-293 |
|
|
|
|
|
|
|
|
clinical, 267-270, 273-276 |
|
|
|
|
|
|
|
|
clinical pathology in, 379-384 |
|
|
|
|
|
|
|
|
clinical pharmacology in, 296-314 |
|
|
|
|
|
|
|
|
concepts, 19, 20 |
|
|
|
|
|
|
|
|
cost containment and, 55-73 |
|
|
|
|
|
|
|
|
determination of endpoints in, 25, 26 |
|
|
|
|
|
|
|
|
dosage establishment in, 21-25 |
|
|
|
|
|
|
|
|
excipients role in, 188-128 |
|
|
|
|
|
|
|
|
and government, 14 |
|
|
|
|
|
|
|
|
issues in, 19, 20 |
|
|
|
|
|
|
|
|
methodologies, 25-27 |
|
|
|
|
|
|
|
|
nonclinical, 272-273 |
|
|
|
|
|
|
|
|
process, 32-36 |
|
|
|
|
|
|
|
|
product liability issues in, 46-55 |
|
|
|
|
|
|
|
|
science applications in, 299-307 |
|
|
|
|
|
|
|
|
Drug discovery, 778 |
|
|
|
|
|
|
|
|
Drug metabolism, 263 |
|
|
|
|
|
|
|
|
studies, 267-277 |
|
|
|
|
|
|
|
|
Drug Price Competition and Patent/ Term Restoration Act, 65 |
|
|
|
|
|
|
|
|
Drug synthesis, 6 |
|
|
|
|
|
|
|
|
computer assisted, 6 |
|
|
|
|
|
|
|
|
Duragesic, 185 |
|
|
|
|
|
|
|
|
Endothelial Derived Relaxing Factory (EDRF), 6 |
|
|
|
|
|
|
|
|
Endothelin, 6 |
|
|
|
|
|
|
|
|
Ethnobotany, 5 |
|
|
|
|
|
|
|
|
Entrepreneurs, 12 |
|
|
|
|
|
|
|
|
European Commission (EC), 380 |
|
|
|
|
|